To a lesser extent, it is present in the kidneys, biliary tract epithelium, intestine, pancreas, brain, heart, and spleen
(A meeting to evaluate seven of these peptides is set for July.) However, this does not mean that the peptides will automatically receive FDA approval
Pitfalls of Standard Intraocular Pressure-Lowering Drugs On the other hand, the proposed cytoprotective principle of BPC 157 therapy in glaucoma [11] may overwhelm principles commonly acknowledged for potent and efficacious intraocular pressure-lowering drugs
doi: 10.1681/ASN.2010070705 109 LuXHuMC
FDA encourages consumers, patients and health care professionals to report any adverse events or quality problems experienced with the use of compounded drug products to FDAs MedWatch Adverse Event Reporting program: Complete and submit the report online at Medwatch